Pierre Fabre Dermatologie

Pierre Fabre Dermatologie is the specialized medical dermatology division of the Pierre Fabre Group, a French multinational pharmaceutical and dermo-cosmetic company. The company focuses on developing and marketing innovative treatments for a wide spectrum of skin conditions, including inflammatory diseases, skin cancers, and rare pediatric disorders. Its portfolio features prominent products such as Hemangiol for infantile hemangioma and the combination therapy Braftovi and Mektovi for BRAF-mutant melanoma. Pierre Fabre Dermatologie is distinguished by its unique ownership structure, being majority-owned by the Pierre Fabre Foundation, a government-recognized public-interest organization. The company integrates pharmaceutical expertise with dermo-cosmetic science to provide comprehensive skin care solutions globally.